| Eli Lilly and Company (NYSE: LLY) will conduct a conference call for the investment community to provide a pipeline update on its Lilly Diabetes business on Monday, June 11, 2012. The call, which is being held in conjunction with the 72nd American Diabetes Association Scientific Sessions, will include the latest data on the investigational novel basal insulin analog, LY2605541, which Lilly is developing in cooperation with Boehringer Ingelheim. Lilly also will provide a brief update on dulaglutide, its investigational, once-weekly glucagon-like peptide 1 (GLP-1) analog. ... |